Alexei Kharitonenkov
Eli Lilly and Company
Lilly Research Laboratories
BioTechnology Discovery Research
Lilly Corporate Center
USA
Name/email consistency: medium
- FGFs and metabolism. Kharitonenkov, A. Curr. Opin. Pharmacol (2009)
- FGF21: a novel prospect for the treatment of metabolic diseases. Kharitonenkov, A., Shanafelt, A.B. Curr. Opin. Investig. Drugs (2009)
- FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. Kharitonenkov, A., Dunbar, J.D., Bina, H.A., Bright, S., Moyers, J.S., Zhang, C., Ding, L., Micanovic, R., Mehrbod, S.F., Knierman, M.D., Hale, J.E., Coskun, T., Shanafelt, A.B. J. Cell. Physiol. (2008)
- Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. Kharitonenkov, A., Shanafelt, A.B. BioDrugs (2008)
- The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Kharitonenkov, A., Wroblewski, V.J., Koester, A., Chen, Y.F., Clutinger, C.K., Tigno, X.T., Hansen, B.C., Shanafelt, A.B., Etgen, G.J. Endocrinology (2007)
- FGF-21 as a novel metabolic regulator. Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., Sandusky, G.E., Hammond, L.J., Moyers, J.S., Owens, R.A., Gromada, J., Brozinick, J.T., Hawkins, E.D., Wroblewski, V.J., Li, D.S., Mehrbod, F., Jaskunas, S.R., Shanafelt, A.B. J. Clin. Invest. (2005)
